Bulpitt C J, Fletcher A E
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
Med J Aust. 1990 Aug 6;153(S1):S16-9. doi: 10.5694/j.1326-5377.1990.tb136984.x.
When comparing costs and benefits of different medical strategies, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis may be used. Both direct and indirect costs and benefits must be considered. Integrating survival with a measure of quality of life such as a health status index permits calculation of quality of life adjusted years of survival (QALYS). In any trial where it is expected that a more expensive treatment is the most effective, a full economic assessment should be made. Examples are provided from the use of verapamil and propranolol in hypertension, naftidrofuryl in stroke and auranofin in the treatment of rheumatoid arthritis.
在比较不同医疗策略的成本和效益时，可以使用成本效益分析、成本效用分析和成本效益分析。必须同时考虑直接和间接成本及效益。将生存情况与生活质量指标（如健康状况指数）相结合，可计算出生活质量调整生存年数（QALYs）。在任何预计更昂贵的治疗方法最有效的试验中，都应进行全面的经济评估。文中给出了使用维拉帕米和普萘洛尔治疗高血压、萘呋胺治疗中风以及金诺芬治疗类风湿关节炎的实例。
